In vitro antiviral activity of single domain antibody fragments against poliovirus

Antiviral Research

Volumn 87, Issue 2, 2010, Pages 257-264

  Thys, Bert ^a   Schotte, Lise ^a   Muyldermans, Serge ^a,b   Wernery, Ulrich ^c   Hassanzadeh Ghassabeh, Gholamreza ^a,b   Rombaut, Bart ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c CENTRAL VETERINARY RESEARCH LABORATORY   (United Arab Emirates)

Author keywords

Anti poliovirus compound; Antiviral; Nanobody; Poliovirus; VHH

Indexed keywords

ANTIVIRUS AGENT; IMMUNOGLOBULIN G; NANOBODY; UNCLASSIFIED DRUG; VARIABLE PART OF THE HEAVY CHAIN OF A HEAVY CHAIN ANTIBODY; IMMUNOGLOBULIN FRAGMENT;

ANTIVIRAL ACTIVITY; ARTICLE; CAMEL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IN VITRO STUDY; NONHUMAN; POLIOMYELITIS VIRUS 1; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS CAPSID; VIRUS CHARACTERIZATION; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS REPLICATION; ANIMAL; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HELA CELL LINE; MICROBIAL SENSITIVITY TEST; POLIOMYELITIS VIRUS;

ANIMALS; ANTIVIRAL AGENTS; CAMELS; HELA CELLS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MICROBIAL SENSITIVITY TESTS; POLIOVIRUS; VIRUS REPLICATION;

CAMELIDAE; CAMELUS DROMEDARIUS; HUMAN POLIOVIRUS 1; MIRIDAE; POLIOVIRUS;

EID: 77954957478     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.05.012     Document Type: Article

References (34)

1. Ahmad A.L., Dowsett A.B., Tyrrell D.A. Studies of rhinovirus resistant to an antiviral chalcone. Antiviral Res. 1987, 8:27-39.
2. Arbabi G.M., Desmyter A., Wyns L., Hamers R., Muyldermans S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 1997, 414:521-526.
3. Belnap D.M., McDermott B.M., Filman D.J., Cheng N., Trus B.L., Zuccola H.J., Racaniello V.R., Hogle J.M., Steven A.C. Three-dimensional structure of poliovirus receptor bound to poliovirus. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:73-78.
4. Brioen P., Sijens R.J., Vrijsen R., Rombaut B., Thomas A.A., Jackers A., Boeyé A. Hybridoma antibodies to poliovirus N and H antigen. Arch. Virol. 1982, 74:325-330.
5. Collett M.S., Neyts J., Modlin J.F. A case for developing antiviral drugs against polio. Antiviral Res. 2008, 79:179-187.
6. Committee on Development of a Polio Antiviral and its Potential Role in Global Poliomyelitis Eradication, N.R.C. Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report 2006, The National Academies Press, Washington, D.C.
7. Conrath K., Lauwereys M., Wyns L., Muyldermans S. Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J. Biol. Chem. 2001, 276:7346-7350.
8. Conrath K., Lauwereys M., Galleni M., Matagne A., Frere J.M., Kinne J., Wyns L., Muyldermans S. Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae. Antimicrob. Agents Chemother. 2001, 45:2807-2812.
9. De Palma A.M., Vliegen I., De Clercq E., Neyts J. Selective inhibitors of picornavirus replication. Med. Res. Rev. 2008, 28:823-884.
10. Dumoulin M., Conrath K., Van Meirhaeghe A., Meersman F., Heremans K., Frenken L.G., Muyldermans S., Wyns L., Matagne A. Single-domain antibody fragments with high conformational stability. Protein Sci. 2002, 11:500-515.
11. Everaert L., Vrijsen R., Boeyé A. Eclipse products of poliovirus after cold-synchronized infection of HeLa cells. Virology 1989, 171:76-82.
12. Frenken L.G., van der Linden R.H., Hermans P.W., Bos J.W., Ruuls R.C., de Geus B., Verrips C.T. Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae. J. Biotechnol. 2000, 78:11-21.
13. Hamers-Casterman C., Atarhouch T., Muyldermans S., Robinson G., Hamers C., Songa E.B., Bendahman N., Hamers R. Naturally occurring antibodies devoid of light chains. Nature 1993, 363:446-448.
14. Harmsen M.M., Fijten H.P., Dekker A., Eblé P.L. Passive immunization of pigs with bispecific llama single-domain antibody fragments against foot-and-mouth disease and porcine immunoglobulin. Vet. Microbiol. 2008, 132:56-64.
15. Harmsen M.M., van Solt C.B., van Zijderveld-van Bemmel A.M., Niewold T.A., van Zijderveld F.G. Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy. Appl. Microbiol. Biotechnol. 2006, 72:544-551.
16. He Y., Bowman V.D., Mueller S., Bator C.M., Bella J., Peng X., Baker T.S., Wimmer E., Kuhn R.J., Rossmann M.G. Interaction of the poliovirus receptor with poliovirus. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:79-84.
17. He Y., Mueller S., Chipman P.R., Bator C.M., Peng X., Bowman V.D., Mukhopadhyay S., Wimmer E., Kuhn R.J., Rossmann M.G. Complexes of poliovirus serotypes with their common cellular receptor, CD155. J. Virol. 2003, 77:4827-4835.
18. Heinz B.A., Rueckert R.R., Shepard D.A., Dutko F.J., McKinlay M.A., Fancher M., Rossmann M.G., Badger J., Smith T.J. Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound. J. Virol. 1989, 63:2476-2485.
19. Lefranc M.P. IMGT, The International ImMunoGeneTics Information System, http://imgt.cines.fr. Methods Mol. Biol. 2004, 248:27-49.
20. Magliani W., Conti S., Cunha R.L., Travassos L.R., Polonelli L. Antibodies as crypts of antiinfective and antitumor peptides. Curr. Med. Chem. 2009, 16:2305-2323.
21. Minor P.D., Ferguson M., Evans D.M., Almond J.W., Icenogle J.P. Antigenic structure of polioviruses of serotypes 1, 2 and 3. J. Gen. Virol. 1986, 67:1283-1291.
22. Nguyen V.K., Hamers R., Wyns L., Muyldermans S. Camel heavy-chain antibodies: diverse germline V(H)H and specific mechanisms enlarge the antigen-binding repertoire. EMBO J. 2000, 19:921-930.
23. Reading S.A., Dimmock N.J. Neutralization of animal virus infectivity by antibody. Arch. Virol. 2007, 152:1047-1059.
24. 2+ of the neutralization epitopes of poliovirus. J. Gen. Virol. 1985, 66:303-307.
25. Rossmann M.G. Neutralization of small RNA viruses by antibodies and antiviral agents. FASEB J. 1989, 3:2335-2343.
26. Skerra A., Plückthun A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 1988, 240:1038-1041.
27. ter Meulen J., Goudsmit J. Human monoclonal antibodies for prophylaxis and therapy of viral infections. New Concepts of Antiviral Therapy 2006, 479-505. Springer. E. Bogner, A. Holzenburg (Eds.).
28. Thys B., De Palma A.M., Neyts J., Andries K., Vrijsen R., Rombaut B. R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond. Antiviral Res. 2008, 78:278-281.
29. van der Linden R.H., de Geus B., Frenken G.J., Peters H., Verrips C.T. Improved production and function of llama heavy chain antibody fragments by molecular evolution. J. Biotechnol. 2000, 80:261-270.
30. van der Linden R.H., Frenken L.G., de Geus B., Harmsen M.M., Ruuls R.C., Stok W., de Ron L., Wilson S., Davis P., Verrips C.T. Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim. Biophys. Acta 1999, 1431:37-46.
31. Van Bockstaele F., Holz J.B., Revets H. The development of nanobodies for therapeutic applications. Curr. Opin. Investig. Drugs 2009, 10:1212-1224.
32. Verlinden Y., Cuconati A., Wimmer E., Rombaut B. The viral protein 3CD induces an equilibrium between the viral protein and RNA synthesis in a cell-free system for poliovirus replication. Arch. Virol. 2002, 147:731-744.
33. Vincke C., Loris R., Saerens D., Martinez-Rodriguez S., Muyldermans S., Conrath K. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J. Biol. Chem. 2009, 284:3273-3284.
34. World Health Organization. AFP/polio case count. 16-3-2010. http://www.polioeradication.org/casecount.asp.